title: A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
abstract: OBJECTIVE
  To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma.
  
  
  METHODS
  Patients were treated with escalating doses of oblimersen administered by continuous intravenous infusion (CIVI) days 1 to 7, CIVI 5-fluorouracil (5-FU) days 4 to 7, and cisplatin on day 4 every 3 weeks.
  
  
  RESULTS
  Fifteen patients received a total of 49 courses of oblimersen at doses of 3, 5, or 7 mg/kg/d given as a 7 day CIVI in combination with 4 or 5 day CIVI of 5-FU (1000 or 750 mg/m2/d) plus intravenous cisplatin (100 or 75 mg/m2 over 2 hours). The recommended phase II dose of oblimersen was 5 mg/kg/d in combination with 5-FU (750 mg/m2/d for 4 days) and cisplatin (75 mg/m). The most common grade 3 to 4 adverse events that occurred in at least 10% of patients at all dose levels included neutropenia (33%), hypokalemia (27%), infection (20%), and mucositis, fatigue, dizziness, thrombosis, and dehydration (in 13% for each category).
  
  
  CONCLUSIONS
  The combination of oblimersen with 5-FU and cisplatin chemotherapy is feasible in patients with advanced upper gastrointestinal cancer, with antitumor activity observed in gastric carcinoma.
authors.affiliation: Department of Oncology, Montefiore-Einstein Cancer Center, New York Cancer Consortium Coordinating Center, Bronx, New York 10461, USA.
authors.forename: Rachel
authors.initials: R
authors.lastname: Raab
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
authors.forename: Allyson J
authors.initials: AJ
authors.lastname: Ocean
authors.forename: Paul
authors.initials: P
authors.lastname: Christos
authors.forename: Mark
authors.initials: M
authors.lastname: Ramirez
authors.forename: Vincent
authors.initials: V
authors.lastname: Vinciguerra
authors.forename: Andreas
authors.initials: A
authors.lastname: Kaubisch
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004943:Esophagogastric Junction / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D010865:Pilot Projects; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D013873:Thionucleotides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; C408162:oblimersen; D002945:Cisplatin; D005472:Fluorouracil